ArticleAntibiotics (Basel, Switzerland)2022
Prevalence and Molecular Mechanisms of Carbapenem Resistance among Gram-Negative Bacilli in Three Hospitals of Northern Lebanon.
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Resistance to novel antimicrobial agents among NDM-and OXA-48-producing Carbapenem-resistant Enterobacterales in Lebanon.Frontiers in cellular and infection microbiology · 2026Article
- Molecular Epidemiological Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Southern Lebanon.Antibiotics (Basel, Switzerland) · 2025Article
- In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Incidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals.BMC infectious diseases · 2025Observational
- Detection and Genomic Characteristics of NDM-19- and QnrS11-Producing O101:H5Microorganisms · 2025Article
- Nationwide surveillance of carbapenem-resistant Gram-negative pathogens in the Lebanese environment.Applied and environmental microbiology · 2025Article
- Understanding and addressing β-lactam resistance mechanisms in gram-negative bacteria in Lebanon: A scoping review.Heliyon · 2025Review
- Profile of outer membrane proteins of carbapenem-resistant Gram-negative bacilli in Ghana.BMC research notes · 2025Article
- Article
- Characterization ofHeliyon · 2024Article
- Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread ofFrontiers in cellular and infection microbiology · 2024Article
- Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon.Antimicrobial resistance and infection control · 2023Observational
- The emergence of carbapenemase-producingFrontiers in public health · 2023Article
- KPC-ProducingAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Carbapenem resistance (CR) is an emerging health issue. Epidemiological surveys on carbapenem-resistant Gram-negative bacilli (CR-GNB) in Lebanon remain scarce. In this study, we determined the prevalence of CR-GNB isolated between 2015 to 2019 in three hospitals in northern Lebanon: 311 CR-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.